Fig. 1

Selonsertib administration ameliorates LPS/GalN-induced liver failure. a Serum levels of ALT, AST, and TBIL were elevated by LPS/GalN injection (vehicle group) and decreased by selonsertib treatment in a dose-dependent manner. b Pathological changes in the liver tissue were shown using H&E staining. c The serum levels of inflammatory cytokines were determined by CBA cytokine analysis. d, e Western blot analysis and grey value assay of p-JNK and JNK expression levels in murine liver samples from different groups (2 from 6 samples are shown in the blots). f, f Serum levels of ALT, AST, and TBIL (f) and H&E staining (g) in LPS/GalN-injected mice treated with vehicle, selonsertib, or selonsertib combined with anisomycin. Data are presented as the mean ± SD (n = 6). *P < 0.05 vs. vehicle; **P < 0.01 vs. vehicle; ***P < 0.001 vs. vehicle; ^#P < 0.05; ^##P < 0.01; ^###P < 0.001; ns not significant, NC normal control, SEL15 selonsertib (15 mg/kg), SEL30 selonsertib (30 mg/kg), SEL60 selonsertib (60 mg/kg), AN anisomycin (20 mg/kg)